Type 2 diabetes (T2D) is a chronic metabolic disorder characterised by insulin resistance and impaired insulin secretion, ...

Patients with asthma and T2 diabetes using SGLT2 inhibitors have a significantly decreased mortality risk within 30 days of an asthma exacerbation.

SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases.

Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases ...

Real-world data reinforce SGLT2 inhibitors as first-line therapy for frail, older adults with heart failure with preserved ...

In older adults with cardiovascular disease, SGLT2 inhibitors significantly reduced the risk for the composite outcome of hospitalization or urgent visits for heart failure and cardiovascular death.

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors used to treat type 2 diabetes are associated with an 11% lower risk of autoimmune rheumatic diseases, such as rheumatoid arthritis and lupus, ...

SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis. After adjustments, patients on SGLT2 inhibitors had a significantly reduced risk of progression to severe ...